Mandate

Vinge advises Irisity AB in connection with the acquisition of Ultinous and a directed share issue

Vinge advises Irisity AB in connection with the acquisition of Ultinous and a directed share issue

Vinge advises Irisity AB (publ) in connection with the acquisition of Ultinous Zrt., a Swedish-Hungarian AI inventor, for a consideration of SEK 45 million, on a cash and debt free basis and assuming normalized working capital, which will be paid through an issue in kind entailing 9,000,000 new shares in Irisity at a subscription price of SEK 5.00 per share. In conjunction with the Acquisition Stockhorn Capital AB (founded by Gustav Andersson and Inna Kaushan) will invest SEK 45 million in Irisity through a directed share issue on the same terms as in the In-kind Issue, i.e., SEK 5.00 per share. The transaction will be subject to national FDI Regulation requiring approval from Swedish and Hungarian authorities and Iristy's EGM resolving to authorize the board of directors to resolve on the share issues. As part of the acquisition and directed share issue, Irisity and Stockhorn Capital will also enter into a loan agreement pursuant to which Stockhorn Capital will lend Irisity an amount of SEK 15 million.

Vinge's team consists of Anders Strid, Edin Agic and Fredrik Löwenclou.

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025